Zevra Therapeutics, Inc. Payments of Stock Issuance Costs
Zevra Therapeutics, Inc. (ZVRA) reported Payments of Stock Issuance Costs of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-11-07
- Zevra Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2023-09-30 was $0.00.
- Zevra Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-12-31 was -$68.00K, a 274.36% decline year-over-year.
- Zevra Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. payments of stock issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Zevra Therapeutics, Inc. payments of stock issuance costs for fiscal 2021 was $1.34M, a 1492.86% increase from fiscal 2020.
- Zevra Therapeutics, Inc. payments of stock issuance costs for fiscal 2020 was $84.00K.
- Zevra Therapeutics, Inc. payments of stock issuance costs for fiscal 2018 was $184.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | -$68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$68.00K derived: sum of 2 quarters · filed 2023-11-07 | -$68.00K derived: sum of 3 quarters · filed 2023-11-07 | $0.00 10-K · filed 2023-03-07 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $68.00K 10-Q · filed 2023-11-07 | $107.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $68.00K 10-Q · filed 2023-08-14 | $107.00K derived: sum of 3 quarters · filed 2023-08-14 | $282.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $68.00K 10-Q · filed 2022-05-12 | $107.00K derived: sum of 2 quarters · filed 2023-03-07 | $282.00K derived: sum of 3 quarters · filed 2023-03-07 | $300.00K derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $214.00K derived: sum of 2 quarters · filed 2023-03-07 | $232.00K derived: sum of 3 quarters · filed 2023-03-07 | $1.34M 10-K · filed 2023-03-07 |
| 2021-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $193.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.30M 10-Q · filed 2022-11-10 | $1.29M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.12M 10-Q · filed 2022-08-12 | $1.11M derived: sum of 3 quarters · filed 2022-08-12 | $1.11M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.11M 10-Q · filed 2022-05-12 | $1.09M derived: sum of 2 quarters · filed 2022-05-12 | $1.09M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$13.00K derived: sum of 2 quarters · filed 2022-03-31 | $84.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $97.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $97.00K 10-Q · filed 2021-08-13 | |||
| 2018-12-31 | $184.00K 10-K · filed 2020-02-28 | |||
| 2014-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $163.00K 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | $13.00K 10-Q · filed 2015-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |